MR-708

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameMR-708
Drug Alias NameMR-708
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors agonists
TargetsDopamine receptors
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityCocaine-Related DisordersSubstance-Related Disorders +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesIran +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedea Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institute On Drug AbuseAmerican Friends Of Rabin Medical Center IncTehran University Of Medical Sciences +[6] 
Active IndicationsN/A
Inactive IndicationsAttention Deficit Disorder with HyperactivityCocaine-Related DisordersSubstance-Related Disorders +[7] 

Other Information

ATC CodeN/A
Related LinksN/A